Back to Search Start Over

Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Authors :
Mehra T
Lupatsch JE
Koessler T
Dedes K
Siebenhüner AR
von Moos R
Wicki A
Schwenkglenks ME
Source :
PloS one [PLoS One] 2024 Dec 12; Vol. 19 (12), pp. e0315976. Date of Electronic Publication: 2024 Dec 12 (Print Publication: 2024).
Publication Year :
2024

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0301271.].<br /> (Copyright: © 2024 Mehra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
1932-6203
Volume :
19
Issue :
12
Database :
MEDLINE
Journal :
PloS one
Accession number :
39666698
Full Text :
https://doi.org/10.1371/journal.pone.0315976